VISUAL FIELD DEFECTS SECONDARY TO CABERGOLINE USE IN A PATIENT WITH PITUITARY TUMOR

Abstract

Prolactinoma is the most common functional pituitary macroadenoma. It is usually treated with dopaminergic agonists, among them cabergoline, which decreases tumor size and consequently the symptoms caused by the tumor. An uncommon complication to this treatment is alterations in the visual field. In the majority of cases, symptoms improve with the discontinuation of the drug. Owing to the diagnostic challenge, we present the following clinical case.

Keywords

• Cabergoline
• Adverse effects
• Prolactinoma
• Visual Fields
• Pituitary Neoplasms.